Table 1.
Univariate analysis for neuroserpin decrease.
| Neuroserpin decrease within first 24 h ≥70 ng/mL n = 70 |
Neuroserpin decrease within first 24 h <70 ng/mL n = 59 |
p | |
|---|---|---|---|
| Female, % | 30.0 | 55.9 | 0.003 |
| Age, years | 69.9 ± 10.6 | 75.2 ± 7.5 | 0.004 |
| Time from onset, h | 4.8 ± 2.2 | 4.5 ± 2.1 | 0.816 |
| TOAST | 0.051 | ||
| - Atherothrombotic, % | 17.1 | 18.6 | |
| - Cardioembolic, % | 35.7 | 49.2 | |
| - Lacunar, % | 18.6 | 3.4 | |
| - Indeterminated, % | 28.6 | 28.8 | |
| History of hypertension, % | 57.1 | 69.5 | 0.103 |
| History of diabetes, % | 22.9 | 28.8 | 0.284 |
| History of dyslipemia, % | 21.4 | 25.4 | 0.371 |
| History of atrial fibrillation, % | 20.0 | 32.2 | 0.084 |
| Previous stroke, % | 2.9 | 15.3 | 0.013 |
| Systolic BP on admission, mm Hg | 147.9 ± 23.6 | 145.6 ± 18.8 | 0.885 |
| Diastolic BP on admission, mm Hg | 81.3 ± 14.2 | 71.6 ± 12.2 | 0.062 |
| Maximum temperature 24 h (°C) | 36.7 ± 0.4 | 36.7 ± 0.5 | 0.943 |
| Glycemia, mg/dL | 120.4 ± 25.3 | 183.7 ± 87.4 | 0.001 |
| Leukocyte count, 103/mL | 8.7 ± 2.4 | 9.2 ± 2.8 | 0.427 |
| Fibrinogen, mg/dL | 386.9 ± 105.2 | 428.1 ± 136.2 | 0.080 |
| Early neurological deterioration, % | 2.9 | 25.4 | <0.0001 |
| NIHSS on admission | 5 [3,10] | 14 [10,16] | <0.0001 |
| Infarct volume, mL | 18.2 ± 20.9 | 44.4 ± 36.3 | <0.0001 |
| Molecular markers of brain damage | |||
| Glutamate 24 h, μM | 67.7 ± 54.4 | 149.9 ± 36.3 | <0.0001 |
| IL-6 24 h, pg/mL | 18.4 ± 3.2 | 29.2 ± 8.1 | <0.0001 |
| ICAM-1 24 h, ng/mL | 344.7 ± 122.5 | 430.2 ± 79.1 | <0.0001 |
| Active MMP-9 24 h, ng/mL | 23.9 ± 8.7 | 32.3 ± 11.1 | <0.0001 |
| cFn 24 h, μg/mL | 7.6 ± 1.9 | 13.1 ± 5.6 | <0.0001 |
Baseline clinical characteristics, stroke subtype, vascular risk factors, biochemical parameters, neuroimaging findings and molecular markers of brain damage in patients with a neuroserpin decrease within the first 24 hours ≥ 70 ng/mL or < 70 ng/mL.